New triple therapy aims to shrink tough liver tumors

This study tests whether adding a liver-directed chemotherapy infusion (HAIC) to a standard two-drug combination (lenvatinib and a PD-1 inhibitor) helps people with advanced liver cancer that has invaded major blood vessels or bile ducts. About 150 adults will receive either the triple therapy or the two-drug combo alone. The goal is to see if the triple therapy helps people live longer and slows cancer growth, while keeping side effects manageable.